With La Jolla's $500M Giapreza nod, FDA breaks a high-water mark for approvals

With La Jolla's $500M Giapreza nod, FDA breaks a high-water mark for approvals

The FDA approved its 46th med this year, passing 2015's high point for recent years.

The latest drugmaker to benefit from a year-end sprint at the FDA is La Jolla Pharmaceutical Company, which picked up the agency's 46th approval of the year on Thursday. The company's Giapreza passed agency gatekeepers as a treatment for adults with dangerously low blood pressure.